arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

GILEAD SCIENCES, INC.

GILD
$167.62 ▼ -6.83 (-3.92%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
20 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Excellent
Bullish
auto_awesome

Analytical Summary

GILEAD SCIENCES, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $208.5B
Dividend Yield 1.89%
Revenue Growth 2.4% ↘
Op. Margin 34.0% ↗
ROIC 18.3% ↗
FCF / Share $7.60 ↘
Trailing P/E 24.5x
Price / Book 9.2x
FCF Yield 4.5%
Debt / Equity 1.10
info Valuation on last close. End-of-day price, Nov 5, 2026.

20-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$29.44B
↑ +2.4% —
Net Income Profit after all expenses
$8.51B
↑ +1672.9% —
Operating Margin Operating profit as % of sales
34.0%
↑ +488.9% 89th
FCF / Share Free cash flow per share
$7.60
↓ -8.0% —
Long-Term Debt Long-term obligations
$24.94B
↓ -6.6% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
91
Returns ↑
95
Financial Health ↓
54
Cash Quality ↓
70

Dividend History

Dividend / share · sourced from SEC filings
$3.16 Latest / share
+2.6% YoY

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 20 years · 76 quarters